You know what they say -- adapt or die. Investment banks better quickly figure out a Twitter strategy because their research departments are becoming obsolete. Mutual funds and hedge fund managers who, for various reasons, either are Twitter-blocked or scoff at it, are already at a significant disadvantage. Ironically, retail investors, facing no compliance issues with Twitter, are actually benefiting more than a lot of Wall Street right now.
I have long hesitated to share a list of my favorite/essential biotech Twitter followers because, invariably, someone important is omitted and feelings get hurt. With that caveat, however, here are 16 people -- all non-journalists -- contributing fantastic analysis and information to the Twitter biotech stream. I learn something from these people almost every day. If you follow them, you'll benefit too.
Alfredo is a professor in neurobiology. Read his tweets and learn.
$MYGN more hurts -> Cigna to Become First US Health Insurer to Require Genetic Counseling Nationwide http://t.co/rglNUmtlfp— Andy Biotech (@AndyBiotech) August 29, 2013Andy is non-stop vacuum cleaner of biotech information. The man doesn't sleep. He sucks up essential biotech data and retweets it to everyone. For free.
$ASTX IR are full of it, nothing material about what they did. Its called premature ejaculation— Patrick Crutcher (@chasingthealpha) August 28, 2013Patrick wants to be as skeptical as I am, but c'mon, no one is going to out-cynic the king of all cynics! Co-founder of Chimera Research Group, which is an good example of how quality, independent biotech research is coming of age via Twitter.
$RIGL's new mission statement...'this was not the result we expected'— zach (@zbiotech) August 26, 2013Zach is a buyside health care analyst who straddles the worlds of fundamental analysis and trading. I'm endeared to his snark and contempt for sell-side B.S.
Simprevir +Sofosbuvir ±ribavirin 12w regimen has already seen 3/54 pntnts relapse within 4w of EoT; not great, IMO: http://t.co/jT6gKDVTB6— Roy Friedman (@DewDiligence) August 28, 2013Roy distrusts everything and everyone. It's why I love him.
$IMGN news is not new at all - license granted pursuant to the terms of an EXISTING Multi-Target agrmnt entered into by IMGN + $LLY in 2011— Ian Estepan (@ianestepan) August 28, 2013Ian is another buyside vanguard on Twitter. If you want to know what Wall Street is thinking, saying or doing about a biotech stock, Ian is the guy to follow.
Datapaloozza for $RNA $GSK b4 year end, $RNA lockup expiry is 12/25/13, low liquidity during data evts.. non-US dystro, US P2, non-US P3.— Sport234a2b (@Sport234a) August 28, 2013@sport234a2b loves to dig. Deep knowledge. Great researcher.
Onyx in the 90s was a pioneer of anti-cancer Rx viruses... Now bought by Amgen... which has leading anti-cancer virus program. Full circle.— Bruce Booth (@LifeSciVC) August 26, 2013Bruce is a Boston venture capitalist/rock star. He doesn't tweet enough, maybe inclusion on this list will prompt him to tweet more. Essential insight into private health care investing.
$ARAY's new CEO has been there for almost exactly a year now...looks like he's starting to hit a stride. http://t.co/ruo1zyB8XA— Brad Loncar (@bradloncar) August 28, 2013I appreciate Brad's optimism and his leadership on corporate governance issues. His long-term, fundamental approach to biotech investing is a welcome pushback against the short-term trading tide.
I am honestly shocked at the silence of the urology community on twitter and otherwise #samadigate @AmerUrological should issue statement— daviesbj (@daviesbj) August 29, 2013Dr. Ben Davies: Urologic Oncologist. Surgeon. Steelers fanatic. Braggart. Funny as hell.
Looks like it is another low volume sell of in $PCYC sort of day. Figured it would catch more of a bid if the market recovered.— David Sobek (@dsobek) August 28, 2013David Sobek is a contributor to TheStreet's biotech coverage for good reason.
$SGMO buys Ceregene for $1m upfront for patents apparently. Co was $CEGE spinout and has failed every clinical trial— Andrew G. (@BioDueDiligence) August 26, 2013Andrew is always deep in the biotech conversation. Excellent source for background information and stays crazily up-to-date with a long list of biotech stocks.
'Gravity' research's whole short thesis in a nutshell seems to be 'what goes up, must come down'. Okay then. $RPTP— Vikram Khanna (@VikramKhanna_) August 29, 2013Vikram is a relatively new Twitter follow for me. I've been impressed so far.
$RGDO closes offering. Appears no investor interest in over-allotment of 925K shares http://t.co/wTWWHRWyV0— j l (@lomu_j) August 27, 2013JL lives inside SEC filings.
$GSK $RNA Drisapersen ph3 study is marked completed on Aug 23: http://t.co/qI8DOzz18i— JQ (@jq1234t) August 28, 2013JQ works in the bio-pharma industry. He knows where the bodies are buried.
$OREX DMC recommends Light study to continue.Interim analysis by Dec & potential resubmission of Contrave NDA by EOY. http://t.co/DsDu45cyXt— Bio Stocks (@BioStocks) August 27, 2013Following Bio Stocks is like having a direct connection to the Bloomberg newswire. I sometimes think he tweets headlines before they're even published. That's my list. Yes, I left off some really good people so apologies. No offense intended. You should check out my entire Twitter follow list -- folks are on there for good reason. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein